These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies. Li H; Hu J; Luo X; Bode AM; Dong Z; Cao Y Cancer Sci; 2018 Jul; 109(7):2101-2108. PubMed ID: 29751367 [TBL] [Abstract][Full Text] [Related]
26. Detection of Epstein-Barr virus infection and gene expression in human tumors by microarray analysis. Li C; Chen RS; Hung SK; Lee YT; Yen CY; Lai YW; Teng RH; Huang JY; Tang YC; Tung CP; Wei TT; Shieh B; Liu ST J Virol Methods; 2006 May; 133(2):158-66. PubMed ID: 16384612 [TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for Epstein-Barr virus-associated cancers in children. Straathof KC; Bollard CM; Rooney CM; Heslop HE Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735 [TBL] [Abstract][Full Text] [Related]
28. Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development. Dasari V; Sinha D; Neller MA; Smith C; Khanna R Expert Rev Vaccines; 2019 May; 18(5):457-474. PubMed ID: 30987475 [TBL] [Abstract][Full Text] [Related]
31. [Epstein-Barr virus and gastric carcinoma]. Fukayama M Nihon Rinsho; 2012 Oct; 70(10):1715-9. PubMed ID: 23198550 [TBL] [Abstract][Full Text] [Related]
32. Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis. Chen YP; Zhang WN; Chen L; Tang LL; Mao YP; Li WF; Liu X; Zhou GQ; Sun Y; Kang TB; Zeng MS; Liu N; Ma J Oncotarget; 2015 Oct; 6(30):29311-23. PubMed ID: 26336130 [TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus-encoded microRNAs as regulators in host immune responses. Wang M; Yu F; Wu W; Wang Y; Ding H; Qian L Int J Biol Sci; 2018; 14(5):565-576. PubMed ID: 29805308 [TBL] [Abstract][Full Text] [Related]
34. NF-kappaB signaling modulation by EBV and KSHV. de Oliveira DE; Ballon G; Cesarman E Trends Microbiol; 2010 Jun; 18(6):248-57. PubMed ID: 20452220 [TBL] [Abstract][Full Text] [Related]
35. [Hodgkin's disease and Epstein-Barr virus]. Depil S; Moralès O; Auriault C Ann Biol Clin (Paris); 2004; 62(6):639-48. PubMed ID: 15563422 [TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. Deacon EM; Pallesen G; Niedobitek G; Crocker J; Brooks L; Rickinson AB; Young LS J Exp Med; 1993 Feb; 177(2):339-49. PubMed ID: 8381153 [TBL] [Abstract][Full Text] [Related]
37. Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies. Zheng X; Huang Y; Li K; Luo R; Cai M; Yun J Viruses; 2022 May; 14(5):. PubMed ID: 35632758 [TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for Epstein-Barr virus-associated malignancies. Long HM; Parsonage G; Fox CP; Lee SP Drug News Perspect; 2010 May; 23(4):221-8. PubMed ID: 20520851 [TBL] [Abstract][Full Text] [Related]
39. Current Progress in EBV-Associated B-Cell Lymphomas. Pei Y; Lewis AE; Robertson ES Adv Exp Med Biol; 2017; 1018():57-74. PubMed ID: 29052132 [TBL] [Abstract][Full Text] [Related]